These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32839900)

  • 21. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
    Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
    Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
    Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
    J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
    Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.
    Choi HJ; Ryu JM; Kim I; Nam SJ; Kim SW; Yu J; Lee JE; Lee SK
    Breast Cancer Res Treat; 2019 Aug; 176(3):591-596. PubMed ID: 31065874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
    Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
    PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
    Poterala JE; Havighurst T; Braun Wisinski K
    Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy.
    Murphy BM; Hoskin TL; Degnim AC; Boughey JC; Hieken TJ
    Ann Surg Oncol; 2021 Dec; 28(13):8729-8739. PubMed ID: 34275042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.
    Montagna G; Mamtani A; Knezevic A; Brogi E; Barrio AV; Morrow M
    Ann Surg Oncol; 2020 Oct; 27(11):4515-4522. PubMed ID: 32488513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
    Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
    Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    Mukhtar RA; Hoskin TL; Habermann EB; Day CN; Boughey JC
    Ann Surg Oncol; 2021 Oct; 28(11):5867-5877. PubMed ID: 33687613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer.
    McVeigh TP; Al-Azawi D; Kearney DE; Malone C; Sweeney KJ; Barry K; McLaughlin R; Keane M; Kerin MJ
    Clin Breast Cancer; 2014 Feb; 14(1):20-5. PubMed ID: 24157259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
    Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.
    Stafford A; Williams A; Edmiston K; Cocilovo C; Cohen R; Bruce S; Yoon-Flannery K; De La Cruz L
    Ann Surg Oncol; 2020 Nov; 27(12):4669-4677. PubMed ID: 32909130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.
    Takahashi M; Jinno H; Hayashida T; Sakata M; Asakura K; Kitagawa Y
    World J Surg; 2012 Dec; 36(12):2847-52. PubMed ID: 22806206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?
    Mamtani A; Sevilimedu V; Le T; Morrow M; Barrio AV
    Cancer; 2022 Feb; 128(3):471-478. PubMed ID: 34597420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.